Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer has agreed to acquire weight-loss drugmaker Metsera in a transaction that could exceed $10 billion. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront, along with a ...

The Food and Drug Administration may revoke authorization for Pfizer’s COVID-19 vaccine for healthy children under age 5, the pharmaceutical company confirmed, which would limit parents' vaccine ...

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant “experienced potential drug-induced liver injury,” the company said April 14. In dose ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on the bearish thesis of PFE stock.

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

Pfizer has launched a two-pronged litigation effort to stop Novo Nordisk from acquiring a weight loss drug company, filing a breach of contract suit in the Court of Chancery on Friday and an antitrust ...